Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12694069 | 0.86 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL14143440 | 0.86 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL15433976 | 0.86 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL14338223 | 0.85 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL3422142 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL16252050 | 0.85 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL12459423 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL15433977 | 0.83 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL12702959 | 0.80 | SLC6A4 (0.73) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL14427970 | 0.80 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289744-A1 | PROCESS FOR PREPARING OPTICALLY PURE MILNACIPRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | ARCH PHARMALABS LIMITED (IN) | 2012-11-15 | — | — | US | disclosed |
| US-20120289744-A1 | PROCESS FOR PREPARING OPTICALLY PURE MILNACIPRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | ARCH PHARMALABS LIMITED (IN) | 2012-11-15 | — | — | US | disclosed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289744-A1 | PROCESS FOR PREPARING OPTICALLY PURE MILNACIPRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | SLCO1B3, SLCO4C1, SLCO1B1 | SLC6A2 364/4885SLC6A4 150/4885SLC6A3 255/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | SLC6A2 33/4885SLC6A4 65/4885SLC6A3 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.